Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could replace needle biopsies for breast cancer staging

NCT ID NCT07304934

Recruiting now Diagnosis Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study is testing a new blood test called TuFEst that uses DNA fragments and deep learning to stage breast cancer and check if it has spread to lymph nodes. Researchers will enroll 269 breast cancer patients, including those having surgery and those receiving chemotherapy before surgery. The goal is to see if this non-invasive test can accurately predict tumor burden, potentially reducing the need for surgical biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test that helps doctors stage breast cancer more accurately, potentially reducing the need for invasive biopsies.
What could go wrong
This is an early-stage study with only 269 participants. The test may not be accurate enough for widespread use, and results may not apply to all breast cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AXILLARY LYMPH NODE METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma metastatic malignant neoplasm in the lymph nodes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AXILLARY LYMPH NODE METASTASIS BREAST CANCER

Contacts and locations

Locations

  • Second affiliated hospital of Medical school, Zhejiang university

    RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.